V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

PTC Therapeutics Executive Compensation (FY25)

PTCT · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): June 5, 2026
354 figures on this page: 343 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Matthew Klein was paid $23,266,326 in total compensation as Chief Executive Officer and Director for fiscal 2025, and Klein's total moved 214.0% higher from the $7,410,765 reported for fiscal 2024. Shareholders recorded 98.0% support for the say-on-pay proposal at the meeting held June 2, 2026 for fiscal 2025. Companies named in the disclosed peer group include ACADIA Pharmaceuticals Inc., Alkermes plc, Amicus Therapeutics, Inc., Apellis Pharmaceuticals, Inc. and Blueprint Medicines Corp., among others. The 2025 Peer Group includes Axsome Therapeutics, Inc., Harmony Biosciences Holdings, Inc. and Madrigal Pharmaceuticals Corporation.
Chief executive, fiscal 2025
◇
Matthew Klein
Latest say-on-pay support
=
June 2, 2026
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Matthew Klein: $7,410,765 → $23,266,326 (214.0% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is PTC Therapeutics' chief executive and what were they paid?
Matthew Klein was paid $23,266,326 in total compensation as Chief Executive Officer and Director for fiscal 2025. Klein's total moved 214.0% higher from the $7,410,765 reported for fiscal 2024.
What was PTC Therapeutics' say-on-pay result?
Shareholders recorded 98.0% support for the say-on-pay proposal at the meeting held June 2, 2026 for fiscal 2025.
Which companies are in PTC Therapeutics' peer group?
Companies named in the disclosed peer group include ACADIA Pharmaceuticals Inc., Alkermes plc, Amicus Therapeutics, Inc., Apellis Pharmaceuticals, Inc. and Blueprint Medicines Corp., among others. The 2025 Peer Group includes Axsome Therapeutics, Inc., Harmony Biosciences Holdings, Inc. and Madrigal Pharmaceuticals Corporation.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Stuart Peltz
Former Chief Executive Officer
◇—◇◇—◇◇◇
Marcio Souza
Executive Vice President, Chief Operating Officer
◇—◇—◇—◇◇
Pierre Gravier
Executive Vice President, Chief Financial Officer
◇—◇—◇—◇◇
Neil Almstead
Executive Vice President, Chief Scientific Officer
◇—◇◇—◇◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Matthew Klein
Chief Executive Officer
◇—◇◇—◇◇◇
Stuart Peltz
Former Chief Executive Officer
◇—◇◇——◇◇
Marcio Souza
Executive Vice President, Chief Operating Officer
◇—◇—◇—◇◇
Neil Almstead
Executive Vice President, Chief Scientific Officer
◇—◇—◇—◇◇
Pierre Gravier
Executive Vice President, Chief Financial Officer
◇—◇◇—◇◇◇
Lee Golden
Executive Vice President and Chief Medical Officer
◇—◇◇—◇◇◇
Emily Hill
Executive Vice President, Chief Legal Officer
◇—◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Stuart Peltz
Former Chief Executive Officer
Departed during or after this year
◇—◇———◇◇
Matthew Klein
Chief Executive Officer
◇—◇◇◇—◇◇
Marcio Souza
Executive Vice President, Chief Operating Officer
◇—◇—◇—◇◇
Emily Hill
Executive Vice President, Chief Legal Officer
◇—◇—◇—◇◇
Eric Pauwels
Chief Business Officer
◇—◇◇—◇◇◇
Neil Almstead
Executive Vice President, Chief Scientific Officer
◇—◇◇—◇◇◇
Lee Golden
Executive Vice President and Chief Medical Officer
◇—◇◇◇—◇◇
Pierre Gravier
Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Matthew Klein
Chief Executive Officer and Director
◇—◇◇◇—◇◇
Eric Pauwels
Chief Business Officer
◇—◇◇◇—◇◇
Pierre Gravier
Chief Financial Officer
◇—◇◇◇—◇◇
Lee Golden
Executive Vice President and Chief Medical Officer
◇—◇◇◇—◇◇
Neil Almstead
Chief Technical Operations Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Eric PauwelsRSU◇——◇——◇
Eric PauwelsPSU◇◇◇—◇—◇
Lee GoldenPSU◇◇◇—◇—◇
Lee GoldenRSU◇——◇——◇
Matthew KleinRSU◇——◇——◇
Matthew KleinPSU◇◇◇—◇—◇
Matthew KleinRSU◇——◇——◇
Neil AlmsteadRSU◇——◇——◇
Pierre GravierRSU◇——◇——◇
Pierre GravierPSU◇◇◇—◇—◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Matthew KleinRSU◇◇——
Option◇—◇—
PSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Lee GoldenOption◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Neil AlmsteadOption◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
Pierre GravierRSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Eric PauwelsRSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Schmertzler
Board chair
◇◇◇———◇
Emma Reeve
◇◇◇———◇
David P. Southwell
◇◇◇———◇
Mary Smith
◇◇◇———◇
Alethia Young
◇◇◇———◇
Stephanie S. Okey
◇◇◇———◇
Glenn D. Steele, Jr, Allan Jacobson, Matthew B. Klein, Jessica Chutter and Jerome B. Zeldis served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Audit committee chair◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals Inc. ACAD
  • Alkermes plc ALKS
  • Amicus Therapeutics, Inc. FOLD
  • Apellis Pharmaceuticals, Inc. APLS
  • Blueprint Medicines Corp. BPMC
  • Corcept Therapeutics Incorporated CORT
  • Exelixis, Inc. EXEL
  • Halozyme Therapeutics, Inc. HALO
  • Insmed, Inc. INSM
  • Intra-Cellular Therapies, Inc. ITCI
  • Ionis Pharmaceuticals, Inc. IONS
  • Jazz Pharmaceuticals plc JAZZ
  • Pacira BioSciences, Inc. PCRX
  • Sarepta Therapeutics, Inc. SRPT
  • Supernus Pharmaceuticals, Inc. SUPN
  • Ultragenyx Pharmaceutical Inc. RARE
2025 Peer Group
  • Axsome Therapeutics, Inc. AXSM
  • Harmony Biosciences Holdings, Inc. HRMY
  • Madrigal Pharmaceuticals Corporation MDGL

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 2, 2026=◇◇◇
2024June 17, 2025=◇◇◇
2023June 18, 2024=◇◇◇
2022June 6, 2023=◇◇◇
2021June 8, 2022=◇◇◇
2020June 9, 2021=◇◇◇
2019June 10, 2020=◇◇◇
2018June 12, 2019=◇◇◇
2017June 13, 2018=◇◇◇
2016June 9, 2017=◇◇◇
2015June 10, 2016=◇◇◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when PTC Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact PTC Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where PTC Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether PTC Therapeutics' disclosed peer group is defensible, who names PTC Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
354 figures on this page: 343 cited to the filing that reported them, 11 calculated from figures it prints.
343 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001104659-26-071040
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001104659-26-045528
    2025 DIRECTOR COMPENSATION · Grants of Plan-Based Awards in 2025 · Narrative to 2025 Director Compensation Table · Outstanding Equity Awards at December 31, 2025 · and 2 more sections
  3. 0001558370-25-008694
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001558370-25-006007
    Summary Compensation Table
  5. 0001558370-24-009313
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001558370-24-005924
    Summary Compensation Table
  7. 0001070081-23-000033
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001070081-23-000020
    Summary Compensation Table
  9. 0001558370-22-009860
  10. 0001070081-21-000020
  11. 0001070081-20-000108
  12. 0001070081-19-000038
  13. 0001070081-18-000054
  14. 0001070081-17-000104
  15. 0001104659-16-126866
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “PTC Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/PTCT (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about PTC Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers PTC Therapeutics discloses

The companies named in PTCT's own disclosed peer group.

ACADIA Pharmaceuticals Inc.Alkermes plcAmicus Therapeutics, Inc.Apellis Pharmaceuticals, Inc.Exelixis, Inc.Halozyme Therapeutics, Inc.Insmed, Inc.Ionis Pharmaceuticals, Inc.Jazz Pharmaceuticals plcSarepta Therapeutics, Inc.Supernus Pharmaceuticals, Inc.Ultragenyx Pharmaceutical Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy